Dipartimento di Scienze Chimiche, University of Naples Federico II, Naples, Italy.
Istituto Nazionale Biostrutture e Biosistemi-Consorzio Interuniversitario, Rome, Italy.
J Mass Spectrom. 2024 Sep;59(9):e5082. doi: 10.1002/jms.5082.
Clinical expression of coronavirus disease 2019 (COVID-19) infectionis widely variable including fatal cases and patients with mild symptoms and a rapid resolution. We studied saliva from 63 hospitalized COVID-19 patients and from 30 healthy controls by integrating large-scale proteomics, peptidomics and targeted metabolomics to assess the biochemical alterations following the infection and to obtain a set of putative biomarkers useful for noninvasive diagnosis. We used an untargeted approach by using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for proteomics and peptidomics analysis and targeted LC-multiple reaction monitoring/MS for the analysis of amino acids. The levels of 77 proteins were significantly different in COVID-19 patients. Among these, seven proteins were found only in saliva from patients with COVID-19, four were up-regulated and three were down-regulated at least five-folds in saliva from COVID-19 patients in comparison to controls. The analysis of proteins revealed a complex balance between pro-inflammatory and anti-inflammatory proteins and a reduced amount of several proteins with immune activity that possibly favours the spreading of the virus. Such reduction could be related to the enhanced activity of endopeptidases induced by the infection that in turn caused an altered balance of free peptides. In fact, on a total of 28 peptides, 22 (80%) were differently expressed in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and control subjects. The multivariate analysis of such peptides permits to obtain a diagnostic algorithm that discriminate the two populations with a high diagnostic efficiency. Among amino acids, only threonine resulted significantly different between COVID-19 patients and controls, while alanine levels were significantly different between COVID-19 patients with different severity. In conclusion, the present study defined a set of molecules to be detected with a quick and easy method based on mass spectrometry tandem useful to reveal biochemical alterations involved in the pathogenesis of such a complex disease. Data are available via ProteomeXchange with identifier PXD045612.
新型冠状病毒病 2019(COVID-19)感染的临床表现广泛多变,包括致命病例和轻症患者以及迅速缓解的患者。我们通过整合大规模蛋白质组学、肽组学和靶向代谢组学,研究了 63 例住院 COVID-19 患者和 30 例健康对照者的唾液,以评估感染后的生化改变,并获得一组可用于非侵入性诊断的潜在生物标志物。我们使用液相色谱-串联质谱(LC-MS/MS)进行蛋白质组学和肽组学分析的非靶向方法和用于分析氨基酸的靶向 LC-多重反应监测/MS,用于分析。COVID-19 患者的 77 种蛋白质水平差异显著。其中,只有 COVID-19 患者的唾液中发现了七种蛋白质,与对照组相比,COVID-19 患者的唾液中四种蛋白质上调,三种蛋白质下调至少五倍。蛋白质分析显示,促炎蛋白和抗炎蛋白之间存在复杂的平衡,并且几种具有免疫活性的蛋白质的含量减少,这可能有利于病毒的传播。这种减少可能与感染诱导的内肽酶活性增强有关,进而导致游离肽的平衡发生改变。事实上,在总共 28 个肽中,22 个(80%)在严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)和对照中表达不同。对这些肽的多元分析可以获得一种诊断算法,该算法可以以高诊断效率区分两种人群。在氨基酸中,只有苏氨酸在 COVID-19 患者和对照组之间存在显著差异,而丙氨酸水平在 COVID-19 患者中因严重程度不同而存在显著差异。总之,本研究定义了一组可通过基于质谱串联的快速简便方法检测的分子,这些分子可用于揭示涉及如此复杂疾病发病机制的生化改变。数据可通过 ProteomeXchange 获得,标识符为 PXD045612。